Literature DB >> 18952053

Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity.

Ryotaro Iwasaki1, Ken Ninomiya, Kana Miyamoto, Toru Suzuki, Yuiko Sato, Hiromasa Kawana, Taneaki Nakagawa, Toshio Suda, Takeshi Miyamoto.   

Abstract

The balance between osteoclast and osteoblast activity is central for maintaining the integrity of bone homeostasis. Here we show that mice lacking dendritic cell specific transmembrane protein (DC-STAMP), an essential molecule for osteoclast cell-cell fusion, exhibited impaired bone resorption and upregulation of bone formation by osteoblasts, which do not express DC-STAMP, which led to increased bone mass. On the contrary, DC-STAMP over-expressing transgenic (DC-STAMP-Tg) mice under the control of an actin promoter showed significantly accelerated cell-cell fusion of osteoclasts and bone resorption, with decreased osteoblastic activity and bone mass. Bone resorption and formation are known to be regulated in a coupled manner, whereas DC-STAMP regulates bone homeostasis in an un-coupled manner. Thus our results indicate that inhibition of a single molecule provides both decreased osteoclast activity and increased bone formation by osteoblasts, thereby increasing bone mass in an un-coupled and a tissue specific manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952053     DOI: 10.1016/j.bbrc.2008.10.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Mechanical vibration inhibits osteoclast formation by reducing DC-STAMP receptor expression in osteoclast precursor cells.

Authors:  Rishikesh N Kulkarni; Philip A Voglewede; Dawei Liu
Journal:  Bone       Date:  2013-08-28       Impact factor: 4.398

2.  MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling.

Authors:  Yiran Yin; Lian Tang; Jieying Chen; Xiaobo Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

4.  DC-STAMP Is an Osteoclast Fusogen Engaged in Periodontal Bone Resorption.

Authors:  W Wisitrasameewong; M Kajiya; A Movila; S Rittling; T Ishii; M Suzuki; S Matsuda; Y Mazda; M R Torruella; M M Azuma; K Egashira; M O Freire; H Sasaki; C Y Wang; X Han; M A Taubman; T Kawai
Journal:  J Dent Res       Date:  2017-02-15       Impact factor: 6.116

Review 5.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

6.  Vitamin E decreases bone mass by stimulating osteoclast fusion.

Authors:  Koji Fujita; Makiko Iwasaki; Hiroki Ochi; Toru Fukuda; Chengshan Ma; Takeshi Miyamoto; Kimitaka Takitani; Takako Negishi-Koga; Satoko Sunamura; Tatsuhiko Kodama; Hiroshi Takayanagi; Hiroshi Tamai; Shigeaki Kato; Hiroyuki Arai; Kenichi Shinomiya; Hiroshi Itoh; Atsushi Okawa; Shu Takeda
Journal:  Nat Med       Date:  2012-03-04       Impact factor: 53.440

7.  Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Ya-Hui Chiu; Kofi A Mensah; Edward M Schwarz; Yawen Ju; Masahiko Takahata; Changyong Feng; Loralee A McMahon; David G Hicks; Ben Panepento; Peter C Keng; Christopher T Ritchlin
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

8.  Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis.

Authors:  Ya-Hui Grace Chiu; Christopher T Ritchlin
Journal:  Psoriasis Forum       Date:  2012

9.  Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts.

Authors:  Zhiyong Zeng; Chenqing Zhang; Junmin Chen
Journal:  J Bone Miner Metab       Date:  2013-03-24       Impact factor: 2.626

10.  Breaking into bone biology: target practice.

Authors:  Yongwon Choi; Matthew C Walsh; Joseph R Arron
Journal:  Nat Med       Date:  2009-02       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.